Beurs.nl monitor iconMarkt Monitor
  • AEX -3,49 919,26 -0,38%
  • DE40 0,00 23.288,06 0,00%
  • US500^ -12,21 5.664,81 -0,22%
  • US30^ -11,50 41.964,30 -0,03%
  • EUR/USD -0,01 1,0853 -0,51%
  • WTI +1,33 68,38 +1,98%
  • Gold spot -5,63 3.044,62 -0,18%

Onward 2025: Stock Lift-Up

838 Posts
Pagina: 1 2 3 4 5 6 ... 42 »» | Laatste | Omlaag ↓
  1. forum rang 5 K. Wiebes 1 januari 2025 11:55
    www.nature.com/articles/s41591-024-02...

    ..."No serious adverse events were reported that were related to either ARCEX Therapy or study procedures in any of the 64 participants who were exposed to any procedures of the Up-LIFT trial (Table 3). A total of 238 adverse events occurred throughout the duration of the study (Table 3, Extended Data Table 3 and Supplementary Data 2). These adverse events were reported in 50 of the 64 individuals who were exposed to any aspect of the Up-LIFT trial procedures. Three of these 238 adverse events were considered serious due to hospitalization associated with the event yet were unrelated to ARCEX Therapy or study procedures. They included constipation, urinary tract infections and bladder stone. Forty-four non-serious adverse events were related to ARCEX Therapy and were reported in 17 of the 64 participants (Table 3). One of these 44 events was a severe adverse event, which was reported in one participant and was related to the occurrence of severe muscle spasms during one rehabilitation session within the ARCEX Therapy period, but it was unrelated to ARCEX Therapy because the stimulation was not turned on when these spasms occurred. There were no unexpected adverse events"...

    Je zou wellicht iets van hartritmestoornissen verwachten, door die pulsjes;
    maar dat is - vooralsnog - niet zo. Nu gaat dus een aantal revalidatieklinie-
    ken in de VS met ARC-EX aan de slag.
    Ik denk dat wanneer de studieresultaten over 'n periode van 'n maand of 6
    worden bevestigd, de goedkeuring voor thuisgebruik slechts 'n formaliteit
    zal zijn.
  2. Jabu5824 2 januari 2025 10:54
    Gelezen, mooi stuk, positieve resultaten.

    ..."No serious adverse events were reported that were related to either ARCEX Therapy or study procedures in any of the 64 participants who were exposed to any procedures of the Up-LIFT trial (Table 3). A total of 238 adverse events occurred throughout the duration of the study (Table 3, Extended Data Table 3 and Supplementary Data 2). These adverse events were reported in 50 of the 64 individuals who were exposed to any aspect of the Up-LIFT trial procedures. Three of these 238 adverse events were considered serious due to hospitalization associated with the event yet were unrelated to ARCEX Therapy or study procedures. They included constipation, urinary tract infections and bladder stone. Forty-four non-serious adverse events were related to ARCEX Therapy and were reported in 17 of the 64 participants (Table 3). One of these 44 events was a severe adverse event, which was reported in one participant and was related to the occurrence of severe muscle spasms during one rehabilitation session within the ARCEX Therapy period, but it was unrelated to ARCEX Therapy because the stimulation was not turned on when these spasms occurred. There were no unexpected adverse events"...

    Je zou wellicht iets van hartritmestoornissen verwachten, door die pulsjes;
    maar dat is - vooralsnog - niet zo. Nu gaat dus een aantal revalidatieklinie-
    ken in de VS met ARC-EX aan de slag.
    Ik denk dat wanneer de studieresultaten over 'n periode van 'n maand of 6
    worden bevestigd, de goedkeuring voor thuisgebruik slechts 'n formaliteit
    zal zijn.
    [/quote]
  3. forum rang 4 nb 2 januari 2025 11:30
    quote:

    Ponzi_NL schreef op 2 januari 2025 11:04:

    dit kan qua populariteit de nieuwe Galapagos worden
    Krijg je al een st.jv.? Holy Mozes
  4. Ponzi_NL 2 januari 2025 15:17
    Recente analistenrapporten tonen optimisme over ONWARD Medical. KBC Securities heeft op 20 december 2024 het koersdoel verhoogd van €8,70 naar €10,40, met een verwacht rendement van +123,18% en een herhaald koopadvies.

    Daarnaast heeft Degroof Petercam op 23 december 2024 het koersdoel verhoogd van €14,10 naar €16,20, met een verwacht rendement van +247,64% en eveneens een koopadvies.
  5. forum rang 6 Kaviaar 2 januari 2025 16:50
    En dan binnenkort een bericht van overname?
    Het gemiddelde van afgelopen beursdagen (waarbij de koers min of meer gedrukt werd en wordt)…

    Maar, geen zorgen. AFM kijkt mee (met hun ogen dicht, dat wel).
838 Posts
Pagina: 1 2 3 4 5 6 ... 42 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.104
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.044
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.825
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.797
Aedifica 3 925
Aegon 3.258 323.033
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.348
Air France - KLM 1.025 35.260
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.152
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.721
AMG 971 134.210
AMS 3 73
Amsterdam Commodities 305 6.743
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 494
Antonov 22.632 153.605
Aperam 92 15.044
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.930
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.586
ASML 1.766 109.757
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.825
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.442